Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
JAN STAHLBERG Insider Profile
4 Followers
JAN STAHLBERG, Ten Percent Owner at Diamedica Therapeutics, holds 5.22M shares in Diamedica Therapeutics (Ticker: DMAC). Most recently, JAN STAHLBERG Bought $1,200,000 shares of Diamedica Therapeutics on Jul 01, 2024 for an estimated value of 3.00M.
JAN STAHLBERG has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Ten Percent Owner
Roles that JAN STAHLBERG holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by JAN STAHLBERG
JAN STAHLBERG's Trading History
List of latest transactions for each holding click on a transaction to see JAN STAHLBERG's performance on stock
You May Also Like
JAN STAHLBERG insider profile FAQ
What is the percentage of profitable transactions made by JAN STAHLBERG?
The percentage of profitable transactions made by JAN STAHLBERG is ―.
What is the average return per transaction made by JAN STAHLBERG?
The average return per transaction made by JAN STAHLBERG is ―.
What stocks does JAN STAHLBERG hold?
JAN STAHLBERG holds: DMAC stocks.
What was JAN STAHLBERG’s latest transaction?
JAN STAHLBERG latest transaction was an Informative Buy of $3.00M.
What was JAN STAHLBERG's most profitable transaction?
JAN STAHLBERG’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is JAN STAHLBERG's role in Diamedica Therapeutics?
JAN STAHLBERG's role in Diamedica Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.